Phase 1 Trial, Tapinarof vs Vtama Cream, Plaque Psoriasis
Summary
A Phase 1 clinical trial (NCT07546214) has been registered to evaluate therapeutic equivalence and safety between Tapinarof Cream 1% and Vtama® Cream 1% in the treatment of plaque psoriasis. The trial is sponsored by Sun pharma Canada, Inc. and includes a placebo control arm. Participants will be treated with one of the three interventions to assess whether the generic formulation performs equivalently to the reference listed drug.
“To demonstrate therapeutic equivalence and safety of Tapinarof Cream, 1% (Sun pharma Canada, Inc.) and Vtama® (Tapinarof) Cream, 1% in the treatment of plaque psoriasis.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
A Phase 1 clinical trial registration has been added to ClinicalTrials.gov for NCT07546214, which will evaluate therapeutic equivalence and safety of Tapinarof Cream 1% versus Vtama® Cream 1% in treating plaque psoriasis. The study, sponsored by Sun pharma Canada, Inc., includes a placebo control arm.
Pharmaceutical companies engaged in topical dermatological drug development and healthcare providers treating plaque psoriasis patients may find this trial relevant for understanding the emerging therapeutic landscape for tapinarof-based treatments. Patients seeking clinical trial options for plaque psoriasis may wish to consult the ClinicalTrials.gov listing for enrollment information.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
A Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis.
Phase 1 NCT07546214 Kind: PHASE1 Apr 22, 2026
Abstract
To demonstrate therapeutic equivalence and safety of Tapinarof Cream, 1% (Sun pharma Canada, Inc.) and Vtama® (Tapinarof) Cream, 1% in the treatment of plaque psoriasis.
Conditions: Plaque Psoriasis
Interventions: Tapinarof Cream, 1%, Vtama® (Tapinarof) Cream, 1%, Placebo Control
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.